$0.06
+0.00(2.00%)
Mkt Cap $21M
$0.05
$0.62
52-Week Range
At A Glance
1
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
2
Revenue is primarily driven by License (44%) and Product Revenue (24.8%).
3
Most recently: . RESULTS OF OPERATIONS AND FINANCIAL CONDITION On March 2, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ende (2026-03-02).
$21M
Market Cap
$4.9B
Revenue
-$16.1B
Net Income
Employees273
Fundamentals
How The Business Makes Money
Revenue by Segment
License44%($48M)
Product Revenue24.8%($27M)
Product22.5%($25M)
Research And Development Service Revenue7.7%($8M)
Royalty Revenue1%($1M)
Revenue by Geography
JP45.2%($60M)
US36.9%($49M)
CN17.9%($24M)
Activity
What Changed Recently
Company Profile
CIK0001811063
ISINUS67080N1191
CUSIP67080N119
Phone332 208 6102
Address1500 Broadway, New York City, NY, 10036, US
SEC EDGAR